TY - JOUR
KW - buprenorphine
KW - Buprenorphine/therapeutic use
KW - Chronic Disease
KW - Female
KW - Harm Reduction
KW - Hub-and-spoke model
KW - Humans
KW - Medication-assisted therapy (MAT)
KW - Naloxone/therapeutic use
KW - Narcotic Antagonists/therapeutic use
KW - Opiate Substitution Treatment/methods
KW - opioid addiction
KW - Opioid-Related Disorders/diagnosis/drug therapy/epidemiology
KW - Opioid-use disorder (OUD)
KW - Primary Health Care/organization & administration
KW - Risk Factors
KW - Trauma-informed care
KW - Women's Health
AU - A. A. Jacobs
AU - M. Cangiano
A1 - 
BT - Primary care
C5 - Opioids & Substance Use
CP - 4
CY - United States
DO - 10.1016/j.pop.2018.08.002
IS - 4
JF - Primary care
PP - United States
PY - 2018
SN - 1558-299X; 0095-4543
SP - 731
EP - 742
EP - 
T1 - Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders
T2 - Primary care
TI - Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders
U1 - Opioids & Substance Use
U2 - 30401353
U3 - 10.1016/j.pop.2018.08.002
VL - 45
VO - 1558-299X; 0095-4543
Y1 - 2018
ER -